VASCULAR BIOGENICS LTD (VBLT) Stock Analyst Ratings
USA - NASDAQ:VBLT - IL0011327454 - Common Stock
0.156 USD
-0.02 (-8.77%)
0.168 USD
+0.01 (+7.69%)
ChartMill assigns a Buy % Consensus number of 46% to VBLT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.1. This target is 3169.23% above the current price.
VBLT was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about VBLT.
In the previous month the buy percentage consensus was at a similar level.
VBLT was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-07-21 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2022-07-20 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-04-28 | Chardan Capital | Initiate | Buy |
| 2021-06-03 | Roth Capital | Maintains | Buy |
VASCULAR BIOGENICS LTD / VBLT FAQ
What do analysts expect the price target to be for VASCULAR BIOGENICS LTD (VBLT)?
7 analysts have analysed VBLT and the average price target is 5.1 USD. This implies a price increase of 3169.23% is expected in the next year compared to the current price of 0.156.
What is the consensus rating for VBLT stock?
The consensus rating for VASCULAR BIOGENICS LTD (VBLT) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
Can you provide the analyst count for VASCULAR BIOGENICS LTD stock?
The number of analysts covering VASCULAR BIOGENICS LTD (VBLT) is 7.